Publications by authors named "D Christopher Coffey"
Background: Biologic (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) used in the management of rheumatoid arthritis (RA) target inflammatory pathways implicated in the pathogenesis of multiple myeloma (MM). It is unknown whether use of b/tsDMARDs affects the incidence of MM.
Methods: In this cohort study using Veterans Health Administration (VHA) data, we identified Veterans newly diagnosed with RA from 1/1/2002 to 12/31/2018 using diagnostic codes and medication fills.
Maternal age can influence reproductive success and offspring fitness, but the timing, magnitude and direction of those impacts are not well understood. Evolutionary theory predicts that selection on fertility senescence is stronger than maternal effect senescence, and therefore, the rate of maternal effect senescence will be faster than fertility senescence. We used a 36-year study of northern elephant seals (Mirounga angustirostris) to investigate reproductive senescence.
View Article and Find Full Text PDFArticle Synopsis
- In the 1960s, Dr. Waldenström identified "benign monoclonal gammopathy," a condition in asymptomatic patients with detectable monoclonal protein, which later led to the recognition of its potential progression to multiple myeloma by Dr. Kyle in 1978, coining the term MGUS.
- Following this, Drs. Kyle and Greipp in 1980 proposed the term "smoldering multiple myeloma" (SMM) for asymptomatic cases that didn't fit existing definitions, establishing criteria based on plasma cell percentage and serum protein levels.
- Current research focuses on advanced technologies (like whole genome sequencing) to enhance understanding of monoclonal gammopathy and improve individualized
Article Synopsis
- * A phase I clinical trial using the gamma-secretase inhibitor (GSI) crenigacestat alongside anti-BCMA CAR T-cells showed that GSI affected the tumor microenvironment, particularly altering monocyte populations and their gene expression.
- * The study also found that some patients had monoallelic deletion of the BCMA gene after previous treatments, which correlated with shorter progression-free survival, highlighting the need to investigate GSIs with BCMA-targeted therapies for better outcomes. *
This case report describes the clinical course of a patient with relapsed IgA kappa multiple myeloma with high-risk cytogenetics. Initially treated with daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD) then transitioned to lenalidomide maintenance. However, he experienced a relapse and was treated with carfilzomib-based therapy (CFZ) but developed drug-induced thrombotic microangiopathy (DI-TMA).
View Article and Find Full Text PDF